Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 112

1.

The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease.

Zielonka D, Ren M, De Michele G, Roos RAC, Squitieri F, Bentivoglio AR, Marcinkowski JT, Landwehrmeyer GB.

Parkinsonism Relat Disord. 2018 Jan 5. pii: S1353-8020(18)30006-3. doi: 10.1016/j.parkreldis.2018.01.006. [Epub ahead of print]

PMID:
29326033
2.

Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression.

Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, Fliessbach K, Foerstl H, Giese A, Jahn H, Kassubek J, Kornhuber J, Landwehrmeyer GB, Lauer M, Pinkhardt EH, Prudlo J, Rosenbohm A, Schneider A, Schroeter ML, Tumani H, von Arnim CAF, Weishaupt J, Weydt P, Ludolph AC, Yilmazer Hanke D, Otto M; FTLDc study group.

J Neurol Neurosurg Psychiatry. 2017 Nov 15. pii: jnnp-2017-317138. doi: 10.1136/jnnp-2017-317138. [Epub ahead of print]

PMID:
29142138
3.

Body weight is a robust predictor of clinical progression in Huntington disease.

van der Burg JMM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RAC, Aziz NA.

Ann Neurol. 2017 Sep;82(3):479-483. doi: 10.1002/ana.25007. Epub 2017 Aug 22.

PMID:
28779551
4.

High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington's disease expansion mutation carriers shows normal mitochondrial respiratory function.

Buck E, Zügel M, Schumann U, Merz T, Gumpp AM, Witting A, Steinacker JM, Landwehrmeyer GB, Weydt P, Calzia E, Lindenberg KS.

PLoS One. 2017 Apr 13;12(4):e0175248. doi: 10.1371/journal.pone.0175248. eCollection 2017.

5.

Intact sensory-motor network structure and function in far from onset premanifest Huntington's disease.

Gorges M, Müller HP, Mayer IM, Grupe GS, Kammer T, Grön G, Kassubek J, Landwehrmeyer GB, Wolf RC, Orth M.

Sci Rep. 2017 Mar 7;7:43841. doi: 10.1038/srep43841.

6.

Identification of extreme motor phenotypes in Huntington's disease.

Braisch U, Hay B, Muche R, Rothenbacher D, Landwehrmeyer GB, Long JD, Orth M; REGISTRY Investigators of the European Huntington's Disease Network and COHORT Investigators of the Huntington Study Group.

Am J Med Genet B Neuropsychiatr Genet. 2017 Apr;174(3):283-294. doi: 10.1002/ajmg.b.32514. Epub 2016 Nov 21.

PMID:
27868347
7.

The neuropsychology of first impressions: Evidence from Huntington's disease.

Sprengelmeyer R, Young AW, Baldas EM, Ratheiser I, Sutherland CAM, Müller HP, Grön G, Süssmuth SD, Landwehrmeyer GB, Orth M.

Cortex. 2016 Dec;85:100-115. doi: 10.1016/j.cortex.2016.10.006. Epub 2016 Oct 21.

PMID:
27852003
8.

Fast-to-Slow Transition of Skeletal Muscle Contractile Function and Corresponding Changes in Myosin Heavy and Light Chain Formation in the R6/2 Mouse Model of Huntington's Disease.

Hering T, Braubach P, Landwehrmeyer GB, Lindenberg KS, Melzer W.

PLoS One. 2016 Nov 7;11(11):e0166106. doi: 10.1371/journal.pone.0166106. eCollection 2016.

9.

Corrigendum to "Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease" [Parkinsonism Relat. Disord. 25C (2016) 58-64].

Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB; Spanish REGISTRY investigators of the European Huntington's Disease Network, Kulisevsky J.

Parkinsonism Relat Disord. 2016 Oct;31:161. doi: 10.1016/j.parkreldis.2016.08.011. Epub 2016 Aug 25. No abstract available.

PMID:
27567724
10.

Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.

Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB; Spanish REGISTRY investigators of the European Huntington's Disease Network, Kulisevsky J.

Parkinsonism Relat Disord. 2016 Apr;25:58-64. doi: 10.1016/j.parkreldis.2016.02.008. Epub 2016 Feb 11.

PMID:
26898966
11.

Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance.

Keogh R, Frost C, Owen G, Daniel RM, Langbehn DR, Leavitt B, Durr A, Roos RA, Landwehrmeyer GB, Reilmann R, Borowsky B, Stout J, Craufurd D, Tabrizi SJ.

PLoS Curr. 2016 Jan 11;8. pii: ecurrents.hd.8060298fac1801b01ccea6acc00f97cb. doi: 10.1371/currents.hd.8060298fac1801b01ccea6acc00f97cb.

12.

Motor network structure and function are associated with motor performance in Huntington's disease.

Müller HP, Gorges M, Grön G, Kassubek J, Landwehrmeyer GB, Süßmuth SD, Wolf RC, Orth M.

J Neurol. 2016 Mar;263(3):539-49. doi: 10.1007/s00415-015-8014-y. Epub 2016 Jan 13.

PMID:
26762394
13.

Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study.

Klöppel S, Gregory S, Scheller E, Minkova L, Razi A, Durr A, Roos RA, Leavitt BR, Papoutsi M, Landwehrmeyer GB, Reilmann R, Borowsky B, Johnson H, Mills JA, Owen G, Stout J, Scahill RI, Long JD, Rees G, Tabrizi SJ; Track-On investigators.

EBioMedicine. 2015 Aug 4;2(10):1420-9. doi: 10.1016/j.ebiom.2015.08.002. eCollection 2015 Oct.

14.

Fat-free mass and its predictors in Huntington's disease.

Süssmuth SD, Müller VM, Geitner C, Landwehrmeyer GB, Iff S, Gemperli A, Orth M.

J Neurol. 2015 Jun;262(6):1533-40. doi: 10.1007/s00415-015-7753-0. Epub 2015 Apr 23.

PMID:
25904208
15.

A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.

Reilmann R, Rouzade-Dominguez ML, Saft C, Süssmuth SD, Priller J, Rosser A, Rickards H, Schöls L, Pezous N, Gasparini F, Johns D, Landwehrmeyer GB, Gomez-Mancilla B.

Mov Disord. 2015 Mar;30(3):427-31. doi: 10.1002/mds.26174. Epub 2015 Feb 17.

PMID:
25689146
16.

Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntington's disease.

Wolf RC, Thomann PA, Sambataro F, Wolf ND, Vasic N, Landwehrmeyer GB, Süßmuth SD, Orth M.

J Neurol. 2015;262(4):859-69. doi: 10.1007/s00415-015-7642-6. Epub 2015 Jan 28.

PMID:
25626721
17.

Update on Huntington's disease: advances in care and emerging therapeutic options.

Zielonka D, Mielcarek M, Landwehrmeyer GB.

Parkinsonism Relat Disord. 2015 Mar;21(3):169-78. doi: 10.1016/j.parkreldis.2014.12.013. Epub 2014 Dec 19. Review.

PMID:
25572500
18.

Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's disease.

Braubach P, Orynbayev M, Andronache Z, Hering T, Landwehrmeyer GB, Lindenberg KS, Melzer W.

J Gen Physiol. 2014 Nov;144(5):393-413. doi: 10.1085/jgp.201411255.

19.

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.

Süssmuth SD, Haider S, Landwehrmeyer GB, Farmer R, Frost C, Tripepi G, Andersen CA, Di Bacco M, Lamanna C, Diodato E, Massai L, Diamanti D, Mori E, Magnoni L, Dreyhaupt J, Schiefele K, Craufurd D, Saft C, Rudzinska M, Ryglewicz D, Orth M, Brzozy S, Baran A, Pollio G, Andre R, Tabrizi SJ, Darpo B, Westerberg G; PADDINGTON Consortium.

Br J Clin Pharmacol. 2015 Mar;79(3):465-76. doi: 10.1111/bcp.12512.

20.

Impact of the control for corrupted diffusion tensor imaging data in comparisons at the group level: an application in Huntington disease.

Müller HP, Kassubek J, Grön G, Sprengelmeyer R, Ludolph AC, Klöppel S, Hobbs NZ, Roos RA, Duerr A, Tabrizi SJ, Orth M, Süssmuth SD, Landwehrmeyer GB.

Biomed Eng Online. 2014 Sep 1;13:128. doi: 10.1186/1475-925X-13-128.

Supplemental Content

Loading ...
Support Center